AffiliationInstitute for Cancer Studies, Christie Hospital, University of Manchester, Withington, Manchester, UK.
MetadataShow full item record
AbstractAngiogenesis has been validated as a target in ovarian cancer through four randomized trials that have reported improved progression-free survival (PFS) in patients with ovarian cancer whose conventional treatment was supplemented with concurrent and maintenance administration of the antivascular endothelial growth factor (VEGF) antibody, bevacizumab. These trials [the International Collaborative Ovarian Neoplasm Group trial (ICON7), the Gynecologic Oncology Group trial (GOG218), OCEANS and AURELIA] have shown that the tumour vasculature is a valid target throughout the lifetime of patients with ovarian cancer. This review seeks to address some of the remaining questions surrounding the optimal strategy for the use of bevacizumab in ovarian cancer.
CitationAngiogenesis as a target for the treatment of ovarian cancer. 2013, 25 (5):558-65 Curr Opin Oncol
JournalCurrent Opinion in Oncology